Loss of TET2 Facilitates Aggressive Behavior in Cutaneous Melanoma by Inducing PGC1α/Oxidative Phosphorylation (OXPHOS) [0.03%]
TET2丢失通过诱导PGC1α/氧化磷酸化(OXPHOS)促进黑色素瘤的恶性进展
Grant M Fischer,Rui Fang,Shuyun Xu et al.
Grant M Fischer et al.
Background and objectives: Induction of PGC1α/oxidative phosphorylation (OXPHOS) is associated with disease progression and treatment resistance in cutaneous melanoma patients. Loss of the TET2/5-hydroxymethylcytosine (5...
Prurigo nodularis and associated dermatological conditions in Finland from 1995 to 2022 [0.03%]
1995年至2022年芬兰的结节性痒疹及其相关皮肤病状况
Laura Huilaja,Jari Jokelainen,Suvi-Päivikki Sinikumpu
Laura Huilaja
Successful dietary control of tyrosinaemia type II caused by a novel variant in TAT [0.03%]
由TAT新变异引起的酪氨酸血症II型的饮食控制成功案例
Senlin Zhu,Zhongya Song,Zhiming Chen et al.
Senlin Zhu et al.
Four decades of stagnation: A qualitative exploration of the lived experience of Atopic Dermatitis across ethnically and sexually diverse adults in the United Kingdom [0.03%]
英国成人特应性皮炎的现状：一种针对不同族裔和性取向经历者的生活体验定性探究（过去四十年）
Yousaf Aftab,Susan Moloney,Bernard Ho et al.
Yousaf Aftab et al.
Long-term morbidity and quality of life among survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum [0.03%]
Stevens-Johnson综合征/中毒性表皮坏死溶解谱系综合症幸存者长期发病率及生活质量研究
Aaron M Drucker,Elizabeth Williams,Benjamin Kaffenberger et al.
Aaron M Drucker et al.
Sophia Bostwick,Katherine Erickson,Alex G Ortega Loayza
Sophia Bostwick
Caution regarding interpretation of trends for the global burden of atopic dermatitis and asthma [0.03%]
警惕特应性皮炎和哮喘全球疾病负担变动趋势的解释
Sheng-Pei Wang,Elisha Myers,Bernd W M Arents et al.
Sheng-Pei Wang et al.
Ustekinumab as a potential therapeutic agent in Bullous Pemphigoid: a biological and clinical proof-of-concept study [0.03%]
乌斯替单抗治疗大疱性 pemphigoid 的概念验证研究
Vlada Koliadenko,Pascal Joly,Flora Lemaire et al.
Vlada Koliadenko et al.
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage) [0.03%]
莱比库单抗治疗中重度外用疗法继发难治性特应性皮炎成人和青少年患者的疗效和安全性：一项随机、双盲、安慰剂对照的III期临床研究（ADvantage）
Richard B Warren,Marjolein de Bruin-Weller,Athanasios Tsianakas et al.
Richard B Warren et al.
Background: Ciclosporin A (CsA) is approved for severe atopic dermatitis (AD), but its efficacy may not be optimal, and its toxicity limits longer-term use. The recently approved lebrikizumab has demonstrated robust effic...